WASHINGTON, D.C. — August 25, 2025 — The Plasma Protein Therapeutics Association (PPTA) is proud to announce the return of its flagship North American conference, the 33rd Plasma Protein Forum (PPF), taking place October 14-15 in Alexandria, Virginia, at the Westin Alexandria Old Town.
PPF is the premier gathering for the plasma protein therapeutics industry in North America, bringing together industry leaders, policymakers, health care providers, researchers, and patients to explore the latest developments, challenges, and opportunities in the field.
This year’s theme is “Navigating the Winds of Change.” Programming will explore how ongoing research drives advancements in plasma donor safety and plasma-derived therapies (PDTs). Participants will also gain insights into the Trump Administration's trade policies and their impact on plasma, PDTs, and the broader pharmaceutical industry.
Featured sessions of PPF 2025 include:
- PPF will begin with a keynote speech from former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus on regulatory innovation and the future of plasma medicine.
- Then, Day 1 sessions will explore trade policy impacts, donor health research, state-level regulation, manufacturing and testing innovation, and health policy developments, plus ample networking opportunities and the Otto Schwarz Award announcement.
- Day 2 participants will be welcomed with a keynote speech from Dr. Mario Macis, entitled, “Markets in Substances of Human Origin: Societal Benefits, Public Perceptions, and Regulatory Challenges.”
- Next, sessions will focus on challenges and opportunities for anti-D plasma collection, the role of AI in the plasma industry, and continued opportunities for collaboration and networking.
- Panels and speakers can be viewed at www.pptaglobal.org/forum
“PPF is an important moment to bring together the many individuals who play a role in the collection, manufacturing, and use of plasma-derived medicines,” said Anita Brikman, PPTA President and CEO. “As innovation opens new doors for diagnosis and treatment, our community must be prepared to meet increasing clinical need. PPF provides the space to have forward-thinking conversations and build momentum around improving advocacy, access, and awareness.”
Registration is now open at www.pptaglobal.org/forum. Plasma industry professionals, patients, advocates, and health care providers are encouraged to attend. Members of the media are welcome and may email media@pptaglobal.org to request credentials.
To learn more about other upcoming PPTA events, visit www.pptaglobal.org/calendar.